Biodesix Closes Series D Financing - August 2012
Biodesix has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for VeriStrat.
254 Results
Biodesix has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for VeriStrat.
Biodesix announces the U.S. commercial availability of VeriStrat.
Biodesix’ Paul Beresford will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine.
Biodesix received the Product Differentiation Excellence Award for its accomplishments in the cancer diagnostics industry.
Biodesix's Paul Beresford will present at the 2011 Biotech Showcase conference taking place January 10–12th at the Parc 55 Wyndham in San Francisco, CA
Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.
Biodesix announced that the U.S. Patent & Trademark Office has issued four patents for the protection of the company's products and technology.